Goldman Sachs highlights China healthcare for post-AI rotation

Goldman Sachs is shifting focus toward Chinese healthcare equities as a potential successor to the current AI-driven market cycle. Earnings for Chinese stocks tracked by the firm recently reached their highest quarterly growth rate in five years. This performance suggests a fundamental improvement in corporate profitability across the region. Monitor whether capital flows shift from technology sectors into healthcare as investors seek value in emerging earnings growth.